Howard Berman, Coya Therapeutics CEO

Six-per­son ALS biotech wants to go pub­lic — but it’s al­so piv­ot­ing from ear­li­er plans

With an S-1 fil­ing with the SEC on Fri­day, reg­u­la­to­ry T cell op­er­a­tion Coya Ther­a­peu­tics fore­shad­owed its plans to get on Nas­daq. At six full-time em­ploy­ees, the biotech out of Hous­ton would make for a tiny pub­lic com­pa­ny.

The move comes at a time when IPOs in biotech are scarce, as the bear mar­ket con­tin­ues to bat­ter the in­dus­try. In No­vem­ber, Acrivon Ther­a­peu­tics was the lone biotech to make the bold jump while oth­ers like Arti­va, Eli­cio and Emalex backed away from the pub­lic mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA